Top

Supportive Care in Cancer

Published in:

01-09-2008 | Original Article

Less nausea, emesis, and constipation comparing hydromorphone and morphine? A prospective open-labeled investigation on cancer pain

Authors: S. Wirz, H. C. Wartenberg, J. Nadstawek

Published in: Supportive Care in Cancer | Issue 9/2008

Abstract

Goals of work

The purpose of this trial was to evaluate the effect of long-term treatment with either oral sustained-release hydromorphone (HM) or morphine (M) on nausea, emesis, and constipation.

Materials and methods

In a prospective, open-labeled, controlled trial, 100 outpatients with cancer pain and treatment with HM or M were enrolled. Mobility, pain, and gastrointestinal symptoms were assessed by the ECOG performance status, selected items of the EORTC questionnaire and Numerical Rating Scales (NRS). Data were analyzed using descriptive and confirmatory statistics (paired t-test, chi square test, Poisson regression).

Main results

Demographic and medical data were comparable in both treatment groups. Taking into account different conversion factors, opioid doses (M 94.4 mg/d vs. HM 137.6 [HM/M = 1:5], p = 0.05 and HM 206.4 [HM/M = 1:7.5], p = 0.0002, respectively) were higher under hydromorphone and NRS of pain (M 2.3 vs. HM 3.6, p = 0.0002) lower under morphine. Nausea and emesis did not attenuate in 33% of patients. NRS of nausea (M 2.5 vs. HM 1.5; p = 0.01), incidences of emesis (M 0.7/d vs. HM 0.1/d, p = 0.0001), the consumption of antiemetics (M 26 vs. HM 14, p = 0.01), and the number of constipated patients (M 8 vs. HM 2, p = 0.04) were higher in the morphine group. An extended use of substances for symptom control revealed constipating effects (M 31 vs. HM 13, p = 0.0003) and was associated with a higher incidence of constipation in the morphine group.

Conclusions

Symptom control in outpatients with cancer pain may be complicated by a symptom controlling medication. Particularly, antiemetics revealed potentially constipating effects. Despite lower opioid doses, morphine provided a better pain control but produced more side effects. Comparing hydromorphone with morphine, it remains unclear if fewer incidences of constipation and nausea in the hydromorphone group were related to pharmacodynamic effects or to a less effective pain control with significantly higher NRS for pain. However, the conversion factor of oral hydromorphone and morphine needs to be questioned.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, Kaasa S, Klees M, Osoba D, Razavi D, Rofe P, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376PubMedCrossRef

Agachan F, Chen T, Pfeifer J, Reissman P, Wexner SD (1996) A constipation scoring system to simplify evaluation and management of constipated patients. Dis Colon Rectum 39(6):681–685PubMedCrossRef

Agra Y, Sacristan A, Gonzalez M, Ferrari M, Portugues A, Calvo MJ (1998) Efficacy of senna versus lactulose in terminal cancer patients treated with opioids. J Pain Symptom Manage 15(1):1–7PubMedCrossRef

Ashby M, Fleming B, Wood M, Somogyi A (1997) Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients. J Pain Symptom Manage 14(3):157–167PubMedCrossRef

Bennett M, Cresswell H (2003) Factors influencing constipation in advanced cancer patients: a prospective study of opioid dose, dantron dose and physical functioning. Palliat Med 17(5):418–22PubMedCrossRef

Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K (1991) The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7:6–9PubMed

Bruera E, Suarez-Almazor M, Velasco A, Bertolino M, MacDonald SM, Hanson J (1994) The assessment of constipation in terminal cancer patients admitted to a palliative care unit: a retrospective review. J Pain Symptom Manage 9:515–519PubMedCrossRef

Bruera E, Franco JJ, Maltoni M, Watanabe S, Suarez-Almazor M (1995) Changing pattern of agitated impaired mental status in patients with advanced cancer: association with cognitive monitoring, hydration, and opioid rotation. J Pain Symptom Manage 10(4):287–291PubMedCrossRef

Bruera E, Pereira J, Watanabe S, Belzile M, Kuehn N, Hanson J (1996) Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 78:852–857PubMedCrossRef

10.

Campora E, Merlini L, Pace M, Bruzzone M, Luzzani M, Gottlieb A, Rosso R (1991) The incidence of narcotic-induced emesis. J Pain Symptom Manage 6:428–30PubMedCrossRef

11.

Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H, Mercadante S, Pasternak G, Ventafridda V, Expert Working Group of the European Association of Palliative Care Network (2001) Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 19(9):2542–2554PubMed

12.

Davis MP, Walsh D (2000) Treatment of nausea and vomiting in advanced cancer. Support Care Cancer 8(6):444–452PubMedCrossRef

13.

De Stoutz ND, Bruera E, Suarez-Almazor M (1995) Opioid rotation for toxicity in terminal cancer patients. J Pain Symptom Manage 10:378–384PubMedCrossRef

14.

Derby S, Portenoy RK (1998) Assessment and management of opioid-induced constipation. In: Portenoy RK, Bruera E (eds) Topics in palliative care 1. Oxford University Press, New York, pp 95–112

15.

Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, Whitehead WE, Janssens J, Funch-Jensen P, Corazziari E (1993) U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 38(9):1569–1580PubMedCrossRef

16.

Fallon MT, Hanks GW (1999) Morphine, constipation and performance status in advanced cancer patients. Palliat Med 13:159–160PubMedCrossRef

17.

Glare P, Walsh D, Sheehan D (2006) The adverse effects of morphine: a prospective survey of common symptoms during repeated dosing for chronic cancer pain. Am J Hosp Palliat Care 23(3):229–235PubMedCrossRef

18.

Gralla RJ, Roila F, Tonato M, Multinational Society of Supportive Care in Cancer; American Society of Clinical Oncology; Cancer Care Ontario; Clinical Oncological Society of Australia; European Oncology Nursing Society; European Society of Medical Oncology; National Comprehensive Cancer Network; Oncology Nursing Society; South African Society of Medical Oncology (2005) The 2004 Perugia Antiemetic Consensus Guideline process: methods, procedures, and participants. Support Care Cancer 13(2):77PubMedCrossRef

19.

Grilo RM, Bertin P, Scotto di Fazano C, Coyral D, Bonnet C, Vergne P, Treves R (2002) Opioid rotation in the treatment of joint pain. A review of 67 cases. Joint Bone Spine 69(5):491–494PubMedCrossRef

20.

Hays H, Hagen N, Thirlwell M, Dhaliwal H, Babul N, Harsanyi Z, Darke AC (1994) Comparative clinical efficacy and safety of immediate release and controlled release hydromorphone for chronic severe cancer pain. Cancer 74(6):1808–1816PubMedCrossRef

21.

Kalso E, Vainio A (1990) Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 47(5):639–646PubMedCrossRef

22.

Lawlor P, Turner K, Hanson J, Bruera E (1997) Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study. Pain 72:79–85PubMedCrossRef

23.

Lee MA, Leng MEF, Tiernan EJJ (2001) Retrospective study of the use of hydromorphine in palliative care patients with normal and abnormal urea and creatinine. Palliat Med 15:26–34PubMedCrossRef

24.

Levy MH (2003) Management of opioid-induced bowel dysfunction. J Nat Comp Cancer Network 1([Suppl 3]):522–526

25.

Lindley CM, Hirsch JD, O'Neill CV, Transau MC, Gilbert CS, Osterhaus JT (1992) Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1:331–340PubMedCrossRef

26.

Lundin E, Karlbom U, Westlin JE, Kairemo K, Jung B, Husin S, Påhlman L, Graf W (2004) Scintigraphic assessment of slow transit constipation with special reference to right-or left-sided colonic delay. Colorectal Dis 6(6):499–505PubMedCrossRef

27.

Mancini IL, Hanson J, Neumann CM, Bruera ED (2001) Opioid type and other clinical predictors of laxative dose in advanced cancer patients: a retrospective study. J Palliative Med 3(1):49–56CrossRef

28.

Mercadante S (1999) Opioid rotation for cancer pain: rationale and clinical aspects. Cancer 86(9):1856–1866PubMedCrossRef

29.

Mercadante S, Casuccio A, Fulfaro F, Groff L, Boffi R, Villari P, Gebbia V, Ripamonti C (2001) Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 19(11):2898–2904PubMed

30.

Meuser T, Pietruck C, Radbruch L, Stute P, Lehmann KA, Grond S (2001) Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 93(3):247–257PubMedCrossRef

31.

Miller MG, McCarthy N, O'Boyle CA, Kearney M (1999) Continuous subcutaneous infusion of morphine vs. hydromorphone. A controlled trial. J Pain Symptom Manage 18(1):9–16PubMedCrossRef

32.

Moriarty M, McDonald CJ, Miller AJ (1999) A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. J Clin Res 2:1–8

33.

Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655PubMedCrossRef

34.

Potter J, Hami F, Bryan T, Quigley C (2003) Symptoms in 400 patients referred to palliative care services: prevalence and patterns. Palliat Med 17(4):310–314PubMedCrossRef

35.

Radbruch L, Sabatowski R, Loick G, Kulbe C, Kasper M, Grond S, Lehmann K (2000) Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine. Palliat Med 14:111–119PubMedCrossRef

36.

Sarhill N, Walsh D, Nelson KA (2001) Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer 9:84–96PubMedCrossRef

37.

Smith MT, Watt JA, Cramond T (1990) Morphine-3-glucuronide—a potent antagonist of morphine analgesia. Life Sci 47(6):579–585PubMedCrossRef

38.

Staats PS, Markowitz J, Schein J (2004) Incidence of constipation associated with long-acting opioid therapy: a comparative study. South Med J 97(2):129–134PubMedCrossRef

39.

Sykes NP (1998) The relationship between opioid use and laxative use in terminally ill cancer patients. Palliat Med 12(5):375–382PubMedCrossRef

40.

The Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC) (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17:20–28CrossRef

41.

Weinstein SM, Shi M, Buckley BJ, Kwarcinski MA (2006) Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain. Clin Ther 28(1):86–98PubMedCrossRef

42.

Wood MM, Ashby MA, Somogyi AA, Fleming BG (1998) Neuropsychological and pharmacokinetic assessment of hospice inpatients receiving morphine. J Pain Symptom Manage 16(2):112–120PubMedCrossRef

43.

Zeppetella G, O’Doherty CA, Collins S (2000) Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage 20(2):87–92PubMedCrossRef

Title: Less nausea, emesis, and constipation comparing hydromorphone and morphine? A prospective open-labeled investigation on cancer pain
Authors: S. Wirz
H. C. Wartenberg
J. Nadstawek
Publication date: 01-09-2008
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 9/2008
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-007-0368-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Goals of work

Materials and methods

Main results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2008

Apoptotic and inflammation markers in oral mucositis in head and neck cancer patients receiving radiotherapy: preliminary report

The acute effect of tropisetron on ECG parameters in cancer patients

The use and toxicity of steroids in the management of patients with brain metastases

Patient–oncologist communication in advanced cancer: predictors of patient perception of prognosis

Development of a score that predicts survival among patients with bone metastasis revealing solid tumor

Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge

Keynote webinar | Spotlight on antibody–drug conjugates in cancer